{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "14567156",
  "DateCompleted": {
    "Year": "2003",
    "Month": "11",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "11",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0095-4543",
      "JournalIssue": {
        "Volume": "30",
        "Issue": "2",
        "PubDate": {
          "Year": "2003",
          "Month": "Jun"
        }
      },
      "Title": "Primary care",
      "ISOAbbreviation": "Prim Care"
    },
    "ArticleTitle": "Use of sibutramine to treat obesity.",
    "Pagination": {
      "StartPage": "405",
      "EndPage": "viii",
      "MedlinePgn": "405-26, viii"
    },
    "Abstract": {
      "AbstractText": [
        "Medications are useful adjuncts to diet and exercise and may help patients lose weight and maintain significant weight loss (5%-10% from baseline). Pharmacologic approaches are indicated in those patients who have had prior weight-loss attempts, who have a body mass index greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 with comorbidity, and who are motivated and ready to undertake dietary and physical activity changes. This article provides a treatment algorithm to help physicians measure meaningful weight loss and proposes conservative blood pressure limits to guide the long-term prescription of sibutramine. Sibutramine can be a useful tool in the obesity treatment toolbox if used by knowledgeable practitioners."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Pennington Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA. ryandh@pbrc.edu"
          }
        ],
        "LastName": "Ryan",
        "ForeName": "Donna H",
        "Initials": "DH"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Prim Care",
    "NlmUniqueID": "0430463",
    "ISSNLinking": "0095-4543"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Obesity Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cyclobutanes"
    },
    {
      "RegistryNumber": "WV5EC51866",
      "NameOfSubstance": "sibutramine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Obesity Agents"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Cyclobutanes"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Obesity"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Randomized Controlled Trials as Topic"
    }
  ],
  "NumberOfReferences": "55"
}